If RESPIRI can do it with less people, less cash, an unproven metric and arguably an inferior single product why can't ADR and Monaghan make an impact in the US market ?
RESPIRI ANNOUNCES FIRST PATIENTS ENROLLED INTO WHEEZO® REMOTE PATIENT
MONITORING PROGRAMS, FURTHER VALIDATING USA BUSINESS MODEL
Respiri Limited (ASX:RSH)(“Respiri” orthe “Company”), an eHealth SaaS Company supporting respiratory
health management is pleased to announce the enrolment of the first patients into the wheezo®
Remote
Patient Monitoring (RPM) program.
Although not financially material, this event marks a key milestone in the execution of the Company USA
business strategy. Further, it is anticipated that the RPM Current Procedural Terminology (CPT) reimbursement
codesfor the wheezo® RPM program for such patients will be processed and reimbursed by Centers of Medicare
and Medicaid Services (CMS) and other insurers within 45 days, making the wheezo® devicethe first by an Australian
MedTech company to be used for monetary reimbursement; another key event. Respiri anticipates the recently
announced major customers Children’s Hospital of Michigan and the Healthcare Organisation based in North
Carolina to commence onboarding patients on the wheezo® program in the coming month, further validating
the Company USA business strategy.
Add to My Watchlist
What is My Watchlist?
